Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding.
Lucy C WaltersKarl HarlosSimon BrackenridgeDaniel RozbeskyJordan R BarrettVitul JainThomas S WalterChris A O'CallaghanPersephone BorrowMireille ToebesScott G HansenJonah B SachaShaheed AbdulhaqqJustin M GreeneKlaus FrühEmily MarshallLouis J PickerEdith Yvonne JonesAndrew J McMichaelGeraldine M GillespiePublished in: Nature communications (2018)
Through major histocompatibility complex class Ia leader sequence-derived (VL9) peptide binding and CD94/NKG2 receptor engagement, human leucocyte antigen E (HLA-E) reports cellular health to NK cells. Previous studies demonstrated a strong bias for VL9 binding by HLA-E, a preference subsequently supported by structural analyses. However, Mycobacteria tuberculosis (Mtb) infection and Rhesus cytomegalovirus-vectored SIV vaccinations revealed contexts where HLA-E and the rhesus homologue, Mamu-E, presented diverse pathogen-derived peptides to CD8+ T cells, respectively. Here we present crystal structures of HLA-E in complex with HIV and Mtb-derived peptides. We show that despite the presence of preferred primary anchor residues, HLA-E-bound peptides can adopt alternative conformations within the peptide binding groove. Furthermore, combined structural and mutagenesis analyses illustrate a greater tolerance for hydrophobic and polar residues in the primary pockets than previously appreciated. Finally, biochemical studies reveal HLA-E peptide binding and exchange characteristics with potential relevance to its alternative antigen presenting function in vivo.
Keyphrases
- nk cells
- mycobacterium tuberculosis
- pulmonary tuberculosis
- binding protein
- endothelial cells
- public health
- single cell
- healthcare
- hepatitis c virus
- human immunodeficiency virus
- randomized controlled trial
- clinical trial
- amino acid
- crispr cas
- gene expression
- emergency department
- candida albicans
- open label
- ionic liquid
- antiretroviral therapy
- case report
- electronic health record
- adverse drug
- case control